¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå
Breast Cancer Diagnostics
»óǰÄÚµå : 1774685
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 467 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯¹æ¾Ï Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 69¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 47¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â À¯¹æ¾Ï Áø´Ü ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 69¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ À̹Ì¡ ±â¼úÀº CAGR 7.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 30¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ý°Ë¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 13¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀåÀº 2024³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 14¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.2%°¡ µË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.1%¿Í 6.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À¯¹æ¾Ï Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À¯¹æ¾ÏÀÇ Á¶±â ¹ß°ßÀÌ ±× ¾î´À ¶§º¸´Ù Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî?

À¯¹æ¾ÏÀº ¿©ÀüÈ÷ ¼¼°è¿¡¼­ °¡Àå ¹ßº´·üÀÌ ³ô°í »ý¸íÀ» À§ÇùÇÏ´Â ¾Ç¼º Á¾¾ç Áß ÇϳªÀ̱⠶§¹®¿¡ ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀ̱â À§Çؼ­´Â Á¶±â ¹ß°ßÀÌ ÇʼöÀûÀÔ´Ï´Ù. À¯¹æ¾Ï Áø´ÜÀÇ ¹ßÀüÀ¸·Î À¯¹æ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ´É·ÂÀÌ Å©°Ô Çâ»óµÇ¾î Àû½Ã¿¡ °³ÀÔÇÏ°í º¸´Ù È¿°úÀûÀÎ Ä¡·á Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. À¯¹æÃÔ¿µ¼ú, ÃÊÀ½ÆÄ, »ý°Ë µî ÀüÅëÀûÀÎ Áø´Ü ¹æ¹ýÀº ¿©ÀüÈ÷ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÁö¸¸, ¾×ü »ý°Ë ¹× AI Áö¿ø ¿µ»ó Áø´Ü°ú °°Àº »õ·Î¿î ±â¼úÀº ºü¸£°Ô »óȲÀ» ¹Ù²Ù°í ÀÖ½À´Ï´Ù. Á¤ºÎ°¡ Áö¿øÇÏ´Â ÀÎ½Ä °³¼± Ä·ÆäÀΰú Á¤±âÀûÀÎ °ËÁø ÇÁ·Î±×·¥Àº Á¶±â ¹ß°ß ºóµµ¸¦ ³ôÀÌ°í »ýÁ¸À²À» ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ ¼Ö·ç¼Ç°ú ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ ÅëÇÕÀº ƯÈ÷ ¿ø°ÝÁö³ª ¼Ò¿ÜµÈ Áö¿ª¿¡¼­ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀº ¿©ÀüÈ÷ È¿°úÀûÀÎ À¯¹æ¾Ï °ü¸®ÀÇ ÇÙ½ÉÀ̱⠶§¹®¿¡ ¼±º° ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯¹æ¾Ï Áø´ÜÀÇ ÃֽŠÇõ½ÅÀ̶õ?

À¯¹æ¾Ï Áø´Ü ºÐ¾ß´Â Á¤È®µµ Çâ»ó°ú À§¾ç¼º °¨¼Ò¸¦ ½ÇÇöÇÏ´Â ÃÖ÷´Ü ±â¼úÀÇ µµÀÔÀ¸·Î ÁøÈ­Çϰí ÀÖÀ¸¸ç, AI¸¦ Ȱ¿ëÇÑ ¿µ»ó ºÐ¼®, µö·¯´× ¾Ë°í¸®Áò, ¸Ó½Å·¯´× ¸ðµ¨Àº À¯¹æÃÔ¿µ¼ú°ú ÃÊÀ½ÆÄ °Ë»çÀÇ ÇØ¼® Á¤È®µµ¸¦ ³ôÀ̰í ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ºñħ½ÀÀû Áø´Ü ±â¼úÀÎ ¾×ü »ý°ËÀº Ç÷¾× »ùÇÿ¡¼­ ¼øÈ¯ Á¾¾ç DNA(ctDNA)¿Í Á¾¾ç °ü·Ã ¸¶Ä¿¸¦ °ËÃâÇÏ¿© ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3D Åä¸ð½Å¼¼½Ã½º(3D tomosynthesis)ÀÇ ¹ßÀüÀ¸·Î °íÇØ»óµµ À̹ÌÁö¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾î º´º¯À» ´õ Àß ¹ß°ßÇÏ°í ºÒÇÊ¿äÇÑ »ý°ËÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. µðÁöÅÐ º´¸®Çаú Ŭ¶ó¿ìµå ±â¹Ý Áø´Ü Ç÷§ÆûÀº ÀÇ·áÁø °£ÀÇ ¿ø°ÝÁø·á¿Í ¿øÈ°ÇÑ µ¥ÀÌÅÍ °øÀ¯¸¦ °¡´ÉÇϰÔÇÔÀ¸·Î½á À¯¹æ¾Ï Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ºÐÀÚ °Ë»ç ¹× À¯ÀüÀÚ °Ë»ç ¹æ¹ýÀÇ ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó, ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀÌ À¯¹æ¾Ï Áø´ÜÀÇ ¹Ì·¡¸¦ ¸¸µé¾î °¥ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

À¯¹æ¾Ï Áø´Ü ±â¼ú äÅÃÀ» ÁÖµµÇÏ´Â ÀÇ·á ºÎ¹®Àº ¾îµðÀϱî?

À¯¹æ¾Ï Áø´Ü µµ±¸ÀÇ µµÀÔÀº º´¿ø, ¿µ»ó Áø´Ü¼¾ÅÍ, º´¸®°Ë»ç½Ç, À¯¹æ¾Ï Àü¹® Ŭ¸®´Ð µî ´Ù¾çÇÑ ÇコÄÉ¾î ºÐ¾ß·Î È®»êµÇ°í ÀÖ½À´Ï´Ù. º´¿øÀº Á¾ÇÕÀûÀÎ À¯¹æ¾Ï Áø´ÜÀÇ ÁÖ¿ä ¼¾Åͷμ­ ¿ªÇÒÀ» °è¼Ó ¼öÇàÇϰí ÀÖÀ¸¸ç, ÇÑ ÁöºØ ¾Æ·¡¿¡¼­ ´Ù¾çÇÑ ¿µ»ó Áø´Ü ¹× »ý°Ë ÀýÂ÷¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü ¼¾ÅÍ´Â Á¤È®ÇÏ°í ºñħ½ÀÀûÀÎ ½ºÅ©¸®´× ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ÷´Ü À¯¹æ ÃÔ¿µ ¹× MRI ½Ã½ºÅÛÀ» °®Ãß°Ô µÇ¾ú½À´Ï´Ù. º´¸®°Ë»ç½Ç¿¡¼­´Â Á¶Á÷ ºÐ¼®°ú ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÇ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ AI¸¦ Ȱ¿ëÇÑ µðÁöÅÐ º´¸®°Ë»ç µµ±¸¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À̵¿ °ËÁø À¯´Ö°ú ¿ø°ÝÀÇ·á ¼­ºñ½º´Â À¯¹æ¾Ï Áø´Ü ¼­ºñ½º¸¦ ³óÃÌ Áö¿ª°ú ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀ¸·Î È®´ëÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ±â°üµéÀÌ Â÷¼¼´ë Áø´Ü µµ±¸¿¡ ÅõÀÚÇÔ¿¡ µû¶ó À¯¹æ¾Ï °ËÁøÀÇ Á¢±Ù¼º°ú Á¤È®¼ºÀÌ Å©°Ô Çâ»óµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

À¯¹æ¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¿µ»ó ±â¼úÀÇ ¹ßÀü, À¯¹æ¾Ï À¯º´·ü Áõ°¡, Á¤¹Ð Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸¿Í ¾×ü »ý°Ë ±â¼úÀÇ È®´ë, Á¶±â ¹ß°ß ´É·Â °­È­, º¸´Ù Ÿ°ÙÈ­µÈ Ä¡·á Á¢±Ù¹ý µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ À¯¹æ¾Ï °ËÁø ÇÁ·Î±×·¥ ÃßÁø°ú ÀÇ·áºñ Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ Ç÷§Æû, ¿þ¾î·¯ºí À¯¹æ¾Ï Áø´Ü ±â±â, Ŭ¶ó¿ìµå ±â¹Ý Áø´Ü ¼Ö·ç¼ÇÀÇ ÅëÇÕÀ¸·Î ȯÀÚ ¸ð´ÏÅ͸µ°ú µ¥ÀÌÅÍ ºÐ¼®ÀÌ ´õ¿í È¿À²ÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ¿¬±¸±â°ü°ú Àû±ØÀûÀ¸·Î Çù·ÂÇÏ¿© ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Áø´Ü °Ë»ç¸¦ °³¹ßÇÏ¿© À¯¹æ¾Ï °ËÃâÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² À¯¹æ¾Ï Áø´Ü ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϰí ÀÖÀ¸¸ç, Á¶±â¿¡ È¿°úÀûÀ¸·Î Áúº´À» °ü¸®ÇÒ ¼ö ÀÖ´Â »õ·Î¿î °¡´É¼ºÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(À̹Ì¡ ±â¼ú, »ý°Ë, À¯Àüü °Ë»ç, Ç÷¾× °Ë»ç, ±âŸ À¯Çü), Á¦Ç° À¯Çü(±â±â ±â¹Ý Á¦Ç°, Ç÷§Æû ±â¹Ý Á¦Ç°), ¿ëµµ(Áø´Ü¡¤¿¹Ãø ¿ëµµ, ½ºÅ©¸®´× ¿ëµµ, ¿¹ÈÄ ¿¹Ãø ¿ëµµ, Á¶»ç ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤Å¬¸®´Ð ÃÖÁ¾ ¿ëµµ, Áø´Ü ¼¾ÅÍ¡¤ÀÇ·á ¿¬±¸¼Ò ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Breast Cancer Diagnostics Market to Reach US$6.9 Billion by 2030

The global market for Breast Cancer Diagnostics estimated at US$4.7 Billion in the year 2024, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Imaging Techniques, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Biopsy segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 10.2% CAGR

The Breast Cancer Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Breast Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Early Breast Cancer Detection More Important Than Ever?

Breast cancer remains one of the most prevalent and life-threatening malignancies worldwide, making early detection crucial in improving patient survival rates. Advances in breast cancer diagnostics have significantly enhanced the ability to identify the disease at its earliest stages, allowing for timely interventions and more effective treatment strategies. Traditional diagnostic methods, including mammography, ultrasound, and biopsy, continue to play a pivotal role, but emerging techniques such as liquid biopsies and AI-assisted imaging are rapidly transforming the landscape. Government-backed awareness campaigns and routine screening programs have increased the frequency of early detection, leading to improved survival outcomes. Additionally, the integration of digital health solutions and telemedicine platforms is expanding access to diagnostic services, particularly in remote and underserved regions. As early diagnosis remains the cornerstone of effective breast cancer management, continued advancements in screening technologies are expected to drive market growth.

What Are the Latest Innovations in Breast Cancer Diagnostics?

The field of breast cancer diagnostics is evolving with the introduction of cutting-edge technologies that improve accuracy and reduce false positives. AI-powered imaging analysis, deep-learning algorithms, and machine-learning models are enhancing the precision of mammography and ultrasound interpretations, minimizing human error. Liquid biopsy, a non-invasive diagnostic technique, is gaining traction as an alternative to traditional tissue biopsies by detecting circulating tumor DNA (ctDNA) and tumor-associated markers in blood samples. Furthermore, advancements in 3D tomosynthesis provide high-resolution imaging, improving lesion detection and reducing unnecessary biopsies. Digital pathology and cloud-based diagnostic platforms are also revolutionizing breast cancer diagnostics by enabling remote consultations and seamless data sharing among healthcare providers. As research continues to refine molecular and genetic testing methodologies, these innovative approaches are expected to shape the future of breast cancer diagnostics.

Which Healthcare Sectors Are Leading the Adoption of Breast Cancer Diagnostic Technologies?

The adoption of breast cancer diagnostic tools is widespread across various healthcare sectors, including hospitals, diagnostic imaging centers, pathology laboratories, and specialized breast cancer clinics. Hospitals continue to serve as primary centers for comprehensive breast cancer diagnostics, offering a range of imaging and biopsy procedures under one roof. Diagnostic imaging centers are increasingly equipping themselves with state-of-the-art mammography and MRI systems, catering to the growing demand for precise and non-invasive screening solutions. Pathology laboratories are integrating AI-driven digital pathology tools to enhance the efficiency of tissue analysis and biomarker testing. Moreover, mobile screening units and telehealth services are playing a vital role in extending breast cancer diagnostic services to rural and underserved populations. As healthcare facilities worldwide invest in next-generation diagnostic tools, the accessibility and accuracy of breast cancer detection are expected to improve significantly.

What Factors Are Driving Market Growth?

The growth in the breast cancer diagnostics market is driven by several factors, including advancements in imaging technologies, the increasing prevalence of breast cancer, and rising investments in precision diagnostics. The expansion of AI-powered diagnostic tools and liquid biopsy techniques is enhancing early detection capabilities, allowing for more targeted treatment approaches. Government initiatives promoting breast cancer screening programs and increased healthcare expenditure are further fueling market demand. Additionally, the integration of digital health platforms, wearable breast cancer detection devices, and cloud-based diagnostic solutions is streamlining patient monitoring and data analysis. Pharmaceutical and biotech companies are actively collaborating with research institutions to develop biomarker-based diagnostic tests, improving the accuracy of breast cancer detection. As technology continues to advance, the breast cancer diagnostics market is poised for sustained growth, offering new possibilities for early and more effective disease management.

SCOPE OF STUDY:

The report analyzes the Breast Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Imaging Techniques, Biopsy, Genomic Tests, Blood Tests, Other Types); Product Type (Instrument-based Products, Platform-based Products); Application (Diagnostic and Predictive Application, Screening Application, Prognostic Application, Research Application); End-Use (Hospitals and Clinics End-Use, Diagnostic Centers and Medical Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â